An Observational Study For Ambrisentan

Completed

• Conditions: Hypertension, Pulmonary
• Interventions: Drug: ambrisentan

• Registration Number: NCT00679224
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Detailed Description

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Study Timeline

• Study First Submitted: 2008-05-14
• Study First Submitted QC: 2008-05-14
• Study First Posted: 2008-05-16
• Study Start: 2008-06
• Primary Completion: 2013-07
• Study Completion: 2013-07
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-21
• Last Update Posted: 2017-03-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
ambrisentan prescribed subjects	ambrisentan	ambrisentan prescribed subjects

Primary Outcome Measures

Name	Time	Method
safety monitoring

Secondary Outcome Measures

Name	Time	Method
safety monitoring

Trial Locations

Locations (1)

GSK Investigational Site; 🇬🇧 Sheffield, United Kingdom